Toric implantable collamer lens offers good results

Article

Implanting the Toric Implantable Collamer Lens (TICL; STAAR Surgical) to correct various degrees of myopia and compound myopic astigmatism, produces predictable refractive results.

Implanting the Toric Implantable Collamer Lens (TICL; STAAR Surgical) to correct various degrees of myopia and compound myopic astigmatism, produces predictable refractive results, according to Daniel Elies from the Instut Oftalmologic Integral, Barcelona, Spain.

The TICL was implanted into 63 eyes of 36 patients with myopic compound astigmatism. The mean preoperative spherical equivalent (SE) was -10.58±3.41 D and the mean preoperative astigmatism was -3.59±1.38 D. The standard recommendations from the manufacturer regarding preoperative measurements, nomogram and implantation technique were followed.

Following implantation of the TICL, mean SE was -10.26 D (p<0.0001) and mean cylinder was -2.87 D (p<0.0001). Holladay analysis of astigmatism showed a large reduction.

At one-year follow-up, 82.5% of eyes had SE within ±0.50 D and 68.3± had an uncorrected visual acuity (UCVA) equal to or better than the preoperative best corrected visual acuity (BCVA). Approximately 60% of eyes gained at least one line of best spectacle corrected visual acuity (BSCVA). At two weeks postoperatively, four eyes had an intraocular pressure (IOP) over 21 mmHg due to steroids. Two eyes (of the same patient) developed adenoviric KCT and five eyes showed tilted IOL, one of which required repositioning.

Overall, Dr Elies concluded that the TICL offers predictable and effective refractive results.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.